Cathy Reese

Lipocine Inc (NASDAQ: LPCN) is still down 57 percent since the U.S. Food and Drug Administration’s Bone, Reproductive and Urologic Drugs Advisory Committee voted 6-13 on Tlando’s benefit-risk profile. But one Street analyst is not only undeterred but is encouraged by the drug’s...

Viveve Medical Inc (NASDAQ: VIVE) is rapidly expanding — its sales force, its treatment indications, its revenue and its fan base, according to a bullish analyst.  The Rating Empire Asset Management Company’s Dr. Cathy Reese initiated coverage on Viveve Medical with a Buy rating...

Dynavax Technologies Corporation (NASDAQ: DVAX) is awaiting its tryst with the FDA after a failed attempt in August. Against this backdrop, analyst Cathy Reese of Empire Asset Management Company recommended buying the shares of the company ahead of the November PDUFA date. As such, the firm has a...